For research use only. Not for therapeutic Use.
KPT-185(CAT: I030142) is an orally bioavailable and selective inhibitor of CRM1 (chromosome region maintenance 1), a nuclear export protein. By inhibiting CRM1, KPT-185 disrupts the export of tumor suppressor proteins like p53 from the nucleus, resulting in their accumulation and activation. This leads to the induction of apoptosis, cell-cycle arrest, and myeloid differentiation in acute myeloid leukemia (AML) cell lines and patient blasts. KPT-185 has demonstrated potent antiproliferative effects, with IC50 values ranging from 100-500 nM in various leukemia cell lines, including HPB-ALL and MOLT-4, and results in significant G1 phase cell cycle arrest. This compound is highly relevant for Cancer Disease Research, particularly in the development of targeted therapies for AML and other hematologic malignancies.
| CAS Number | 1333151-73-7 |
| Synonyms | propan-2-yl (Z)-3-[3-[3-methoxy-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-enoate |
| Molecular Formula | C16H16F3N3O3 |
| Purity | ≥95% |
| IUPAC Name | propan-2-yl (Z)-3-[3-[3-methoxy-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-enoate |
| InChI | InChI=1S/C16H16F3N3O3/c1-10(2)25-14(23)4-5-22-9-20-15(21-22)11-6-12(16(17,18)19)8-13(7-11)24-3/h4-10H,1-3H3/b5-4- |
| InChIKey | NLNGWFLRRRYNIL-PLNGDYQASA-N |
| SMILES | CC(C)OC(=O)C=CN1C=NC(=N1)C2=CC(=CC(=C2)OC)C(F)(F)F |
